FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
This article was originally published in The Rose Sheet
Executive Summary
In a warning letter published on FDA's website May 2, the agency identifies two Ageless Derma products as unapproved new drugs due to label and website claims touting body structure/function effects. The laundry list of offending claims offers a resource for companies to use in their own claims-compliance efforts.
You may also be interested in...
Nutricosmetics Pose Intriguing Possibilities For Brands That Hit Wall With Skin-Care Claims
Statements about collagen production, maintaining cellular integrity, addressing age spots, even shrinking wrinkles and treating noncystic acne – all are viable structure/function claims for nutricosmetics, assuming there's evidence to back them up. The Rose Sheet discusses the growing opportunity with regulatory and legal experts and provides an overview of the market at present.
FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
MGC Navigates Regulatory Uncertainty With Cannabis Skin Care
US regulations concerning use of cannabinoid CBD in consumer products are complex and hazily defined, representing an additional set of challenges for companies launching CBD-based skin care to an already heavily regulated market. MGC Derma does not expect FDA to come down on its CBD use per se, but the firm's specific product claims could still be subject to scrutiny.